Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Trade Secrets vs. the Public's Right to Know
As part of its efforts to combat rampant drug abuse, the City of Chicago is suing several opioid-drug manufacturers, claiming that they have engaged in “a scheme to misinform the health care community and consumers about the risks, benefits and superiority of the opium-like painkillers” they manufacture. The City agreed to redaction of part of the complaint and some of the pre-suit investigative materials, at the drug manufacturers' request, the manufacturers asserting that these things included confidential company information. But three news outlets ' The Los Angeles Times, USA Today and The Chicago Tribune ' moved in mid-July to intervene in the lawsuit to unseal the redacted materials. They claim that their First Amendment and common law rights to access to judicial proceedings are being limited by the redactions, and that the public has a right to know what is happening in the case. Named in the lawsuit are pharmaceuticals companies Actavis PLC, Cephalon Inc., Endo Health Solutions Inc., Janssen Pharmaceuticals Inc., Johnson & Johnson, the Purdue Frederick Company Inc., Purdue Pharma Inc., Purdue Pharma L.P., and Teva Pharmaceutical Industries, Ltd.
'
Trade Secrets vs. the Public's Right to Know
As part of its efforts to combat rampant drug abuse, the City of Chicago is suing several opioid-drug manufacturers, claiming that they have engaged in “a scheme to misinform the health care community and consumers about the risks, benefits and superiority of the opium-like painkillers” they manufacture. The City agreed to redaction of part of the complaint and some of the pre-suit investigative materials, at the drug manufacturers' request, the manufacturers asserting that these things included confidential company information. But three news outlets ' The Los Angeles Times, USA Today and The Chicago Tribune ' moved in mid-July to intervene in the lawsuit to unseal the redacted materials. They claim that their First Amendment and common law rights to access to judicial proceedings are being limited by the redactions, and that the public has a right to know what is happening in the case. Named in the lawsuit are pharmaceuticals companies
'
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
In June 2024, the First Department decided Huguenot LLC v. Megalith Capital Group Fund I, L.P., which resolved a question of liability for a group of condominium apartment buyers and in so doing, touched on a wide range of issues about how contracts can obligate purchasers of real property.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
Latham & Watkins helped the largest U.S. commercial real estate research company prevail in a breach-of-contract dispute in District of Columbia federal court.